T1	Participants 161 227	in patients with chronic heart failure after myocardial infarction
T2	Participants 361 396	in patients with heart failure (HF)
T3	Participants 557 618	in patients with class II to IV HF and ejection fraction <35%
T4	Participants 773 829	330 patients intended for enrollment, 23 were randomized
T5	Participants 1090 1164	in myoblast-treated patients: 1 (placebo), 3 (low dose), and 4 (high dose)
T6	Participants 1226 1252	in myoblast-treated groups
T7	Participants 1788 1837	in HF patients with postinfarction cardiomyopathy
